CareCost Prior authorization
Required
Check what the payer requires before you schedule Prolia.
Prior authorization · preferred product · clinical criteria · dosing
27 of 30 payer policy sets hold a denosumab policy · source-linked · reviewed August 2026
Aetna + postmenopausal osteoporosis is shown as a live example until you choose a payer.
This payer requires an approval on file before Prolia is purchased or administered for this member.
Precertification of denosumab, or its biosimilar, is required of all Aetna participating providers and members in applicable plan designs
Covered under ICD-10 M81.0.
Postmenopausal osteoporosis - when either of the following criteria is met
What opens in CareCost
Aetna · Prolia · Postmenopausal osteoporosis
For every requirement: the exact payer criteria, the source citation, a check-off, and a save to the patient’s chart.
In CareCost: check off each requirement · save to the patient · print for the chart
Aetna · Prolia · Postmenopausal osteoporosis
You have already checked the policy, indication and covered dose. Open the remaining requirements and work them as a patient checklist.
CareCost tracks Prolia coverage requirements across 27 payer policy sets.
Aetna · Anthem / Elevance · Cigna · UnitedHealthcare · Regence · Premera · BCBS plans + more
Coverage clearance is only the first step.
CareCost carries the same patient through the entire workflow.
Finish this patient’s estimate →22 of 27 commercial payers with a denosumab policy require prior authorization. Clinical criteria, preferred-product and dosing rules vary by plan. Three payers CareCost has read — BCBS Tennessee, HMSA and Kaiser Permanente WA — carry no denosumab policy at all.
22 require PA · 25 have clinical criteria · 9 restrict site of care · 14 prefer a specific product
Many commercial payers require approval before denosumab is purchased or administered.
Coverage depends on the diagnosis in the payer’s denosumab policy — postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, or bone loss from aromatase-inhibitor or androgen-deprivation therapy.
Plans may require a documented fracture-risk threshold (T-score, FRAX probability) or a prior bisphosphonate trial before paying for denosumab.
Some plans prefer a biosimilar — or, less often, still prefer Prolia itself — before covering the alternative.
The billed dose (60 mg every 6 months) must match the diagnosis-specific policy criteria. A 120 mg claim is Xgeva’s dose, not Prolia’s.
Some plans restrict where the injection can be administered.
Some payers will not cover denosumab at the same time as an IV bisphosphonate.
Prolia's label calls for a dental exam before the first dose in patients with risk factors for osteonecrosis of the jaw. Some payer policies list that clearance as a PA-packet item rather than a clinical recommendation only — submit it with the initial request instead of waiting for a request for more information.
Four denosumab biosimilars are now priced below Prolia’s ASP+6% rate (Q3 2026): Stoboclo $25.979, Jubbonti $27.665, Conexxence $28.818, versus Prolia $30.101. A fifth, Enoby, carries no published CMS price at all. Most payer policies CareCost has read now name a preferred product — usually a biosimilar, occasionally Prolia itself.
| Payer | PA? | Preferred / mandated | Reference Prolia? | Notes |
|---|---|---|---|---|
| UnitedHealthcare Commercial |
Yes | Prolia itself, alongside Stoboclo (Q5157) | Covered as a preferred product | One of only two payers CareCost has read that still prefer the brand product |
| Anthem / Elevance Commercial |
Yes | Prolia (J0897) itself | Covered as a preferred product | Non-preferred: Jubbonti, Stoboclo, Conexxence, Bildyos |
| Wellmark BCBS Commercial |
Yes | Jubbonti, Wyost, Stoboclo, Osenvelt | Non-preferred — requires the plan’s exception process | Prolia and Xgeva are both explicitly excluded from the preferred list |
| Independence Blue Cross Commercial |
Criteria-based (no PA) | Jubbonti (Q5136) and Stoboclo (Q5157) | Not named as preferred | Designates two biosimilar families as preferred; no PA required for denosumab at all |
| Excellus BCBS Commercial |
Yes | Enoby and Bildyos | Non-preferred — requires a documented trial and failure of both preferred products first | Prefers Enoby (Q5167), the one denosumab code CMS has never published a payment limit for — and Premera moved Enoby to preferred too. A preferred product with no ASP leaves the practice no Medicare benchmark to price against |
| BCBS South Carolina Commercial |
Yes | Jubbonti (osteoporosis) and Wyost (oncology) | Non-preferred | Names one preferred biosimilar per product line — Jubbonti against Prolia, Wyost against Xgeva — and puts the two Amgen brands in the non-preferred column with the ten other denosumabs |
No prior authorization for Part B denosumab. Coverage follows the diagnosis codes in the Medicare policy — the governing local coverage determinations are published in the CMS Medicare Coverage Database, and a MAC can differ from its neighbour on the same drug.
This is the Original Medicare answer. A Medicare Advantage plan administers the same Part B benefit but can layer its own prior-authorization and preferred-product rules on top — check the plan’s own policy rather than assuming the Original Medicare rules below carry over.
LCD L33394, “Drugs and Biologicals, Coverage of, for Label and Off-Label Uses” (published by Wellpoint Federal for jurisdictions including IL, MN, WI, CT, NY, ME, MA, NH, RI and VT), lists denosumab (Prolia, Xgeva) as covered for its FDA-approved uses and its approved compendia uses. It does not set a T-score threshold, does not require a FRAX calculation, and does not ask for confirmation of calcium and vitamin D status. Those clinical gates come from the FDA label and from commercial payer medical policies — not from this LCD. A biller working a Medicare claim under L33394 does not need to submit DXA or FRAX documentation the LCD never asked for, and a T-score gate that applies to a commercial plan does not automatically apply to a Medicare claim, or the reverse. Read LCD L33394 →
The T-score and DXA requirements are not in the Medicare LCD, but they are common in commercial policy. Aetna, Anthem/Elevance, Arkansas BCBS, BCBS Minnesota, Capital BlueCross, Highmark BCBS, Independence Blue Cross, Horizon BCBS NJ and Cigna each require a baseline dual-energy x-ray absorptiometry (DXA) bone-density scan showing a T-score at or below -2.5 (measured at the spine, femoral neck, total hip, or one-third radius) to document osteoporosis before Prolia is covered.
Payer citation language above is drawn from CareCost’s own denosumab policy corpus (27 payers). Check the specific payer’s language →
It depends on the payer and plan. 22 of the 27 commercial denosumab policies CareCost has read require prior authorization before Prolia is covered. Check this patient’s payer →
Clinical criteria, dosing and preferred-product rules can still apply beyond the diagnosis. Postmenopausal osteoporosis is a covered indication under nearly every denosumab policy CareCost has read. Check coverage →
It depends on the payer. 14 of the 27 payer policies CareCost has read name a preferred denosumab product — sometimes Prolia itself, more often one of the four biosimilars now priced below it. Check preferred-product rules →
CareCost turns the applicable payer policy into a patient-level checklist showing each requirement, what to confirm, and the source language supporting it. Open patient clearance →
Data current: payer policies Aug 2026 · reviewed dates come from each payer
Payer medical and specialty-drug policies · prior-authorization criteria · preferred-product policies · clinical coverage criteria. Medicare coverage from the CMS Medicare Coverage Database. Every CareCost requirement links back to its source policy.